Wells Fargo upgraded Neurocrine to Overweight from Equal Weight with a price target of $170, up from $140.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine, Sentia Medical Sciences extend CRF research collaboration
- Voyager announces selection of development candidate for GBA1 Program
- Neurocrine initiates Phase 1 study of NBI-1065890
- Neurocrine price target raised to $158 from $148 at JPMorgan
- Spruce Biosciences downgraded to Market Perform from Outperform at Leerink